Rsv vaccine
Rsv vaccine has been studied in 6 papers since 2022: 1 observational study in people, 5 reviews; 2 in the past year. The newest paper, Jul 3, 2026: “The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals”.
6 papers study it7 findingsUpdated
See all 6 papers on rsv vaccine
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.
“The vaccine cohort was associated with lower odds of MACCE (OR 0.22; 0.15-0.34; p<0.0001)”
None of its findings points the other way.
- 1 lab in 1 country
- 1 trial, none about aging
- Funder: National Institute of Allergy and Infectious Diseases
- Humans1
What did studies of rsv vaccine find?
2Studies of rsv vaccine measured 2 outcomes: ischemic stroke and respiratory syncytial virus infection.
Ischemic stroke
no changein humans1
1 study
Ischemic stroke
no changein humans1
Rsv vaccine was not clearly linked with ischemic stroke in humans.
“Ischemic stroke did not reach significance at any interval.”
Humans
AHA Scientific Sessions 2025 abstract
Respiratory syncytial virus infection
downin humans1
1 study
Respiratory syncytial virus infection
downin humans1
Rsv vaccine protects against respiratory syncytial virus infection in humans (older adults).
“Three new RSV vaccines now have published data for two seasons, and while direct comparison is not possible due to differences in the timing, methodology and populations studies, all show good efficacy”
Reviewolder adults
Respiratory syncytial virus pulmonary infections in adults - disease burden and prevention
Current opinion in pulmonary medicine
What is rsv vaccine linked with?
5Studies link rsv vaccine with 5 measures, among them dementia, heart failure and myocardial infarction.
Dementia
downin humans1
1 study
Dementia
downin humans1
Rsv vaccine lowers the risk of dementia in humans.
“immunization with the adjuvanted RSV vaccine, also containing AS01, was shown to reduce risk of dementia.”
Review
Infection, vaccination and risk of dementia: a proposed immunological model
Frontiers in immunology
Heart failure
downin humans1OR 0.32
1 study
Heart failure
downin humans1OR 0.32
Rsv vaccine is linked with a lower risk of heart failure in humans (OR 0.32, 95% CI 0.19-0.55, p<0.0001).
“heart failure (OR 0.32; 0.19-0.55; p<0.0001)”
Humans
AHA Scientific Sessions 2025 abstract
Myocardial infarction
downin humans1OR 0.15
1 study
Myocardial infarction
downin humans1OR 0.15
Rsv vaccine is linked with a lower risk of myocardial infarction in humans (OR 0.15, 95% CI 0.08-0.31, p<0.0001).
“acute MI (OR 0.15; 0.08-0.31; p<0.0001)”
Humans
AHA Scientific Sessions 2025 abstract
Mortality
downin humans1OR 0.16
1 study
Mortality
downin humans1OR 0.16
Rsv vaccine is linked with a lower risk of mortality in humans (OR 0.16, 95% CI 0.09-0.27, p<0.0001).
“all-cause mortality (OR 0.16; 0.09-0.27; p<0.0001)”
Humans
AHA Scientific Sessions 2025 abstract
Major adverse cardiovascular and cerebrovascular events
downin humans1OR 0.22
1 study
Major adverse cardiovascular and cerebrovascular events
downin humans1OR 0.22
Rsv vaccine is linked with a lower risk of major adverse cardiovascular and cerebrovascular events in humans (OR 0.22, 95% CI 0.15-0.34, p<0.0001).
“The vaccine cohort was associated with lower odds of MACCE (OR 0.22; 0.15-0.34; p<0.0001)”
Humans
AHA Scientific Sessions 2025 abstract
Trial sponsors
Canadian Immunization Research Network
1 trialPhase 460 people
Funding
1 grant since 2018National Institute of Allergy and Infectious Diseases$2.9M